{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:08:31Z","timestamp":1773187711021,"version":"3.50.1"},"reference-count":12,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2026,2,23]]},"DOI":"10.1080\/10428194.2025.2584682","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T07:00:46Z","timestamp":1762412446000},"page":"718-721","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Real world outcomes of patients with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation after induction with liposomal daunorubicin-cytarabine (CPX-351)"],"prefix":"10.1080","volume":"67","author":[{"given":"Dat","family":"Ngo","sequence":"first","affiliation":[{"name":"Department of Pharmacy, City of Hope","place":["Duarte, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guneet","family":"Kaleka","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles","place":["Los Angeles, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongyun","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Computational and Quantitative Medicine, Division of Biostatistics, City of Hope","place":["Duarte, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Mokhtari","sequence":"additional","affiliation":[{"name":"Department of Computational and Quantitative Medicine, Division of Biostatistics, City of Hope","place":["Duarte, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Tinajero","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, City of Hope","place":["Duarte, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Marcucci","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope","place":["Duarte, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope","place":["Duarte, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod","family":"Pullarkat","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope","place":["Duarte, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caspian","family":"Oliai","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles","place":["Los Angeles, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9302-5041","authenticated-orcid":false,"given":"Amandeep","family":"Salhotra","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope","place":["Duarte, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16359"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2012.10.005"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_438662"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S139450"},{"key":"e_1_3_2_6_1","unstructured":"U.S. Food and Drug Administration. FDA Approves First Treatment for Certain Types of Poor-Prognosis Acute Myeloid Leukemia. FDA August 3. www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-certain-types-poor-prognosis-acute-myeloid-leukemia"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6112"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00134-4"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006468"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-02082-5"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.3826"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014279"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2025.2584682","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T04:42:58Z","timestamp":1773117778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2025.2584682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,23]]}},"alternative-id":["10.1080\/10428194.2025.2584682"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2025.2584682","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-05-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}